Insight Molecular Diagnostics (IMDX) Operating Leases (2018 - 2023)

Insight Molecular Diagnostics has reported Operating Leases for 5 years, with the latest figure at $2.1 million in Q4 2023.

• Quarterly Operating Leases fell 22.98% year-over-year to $2.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.1 million (down 22.98% YoY) and the FY2023 annual result came in at $2.1 million, down 22.98% from the prior year.
• Operating Leases eased to $2.1 million in Q4 2023 per IMDX's latest filing, from $2.4 million in the prior quarter.
• Over five years, Operating Leases peaked at $3.9 million in Q3 2020 and troughed at $2.1 million in Q4 2023.
• A 4-year average of $2.8 million and a median of $2.7 million in 2019 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2019 and 2023: Operating Leases soared 1331.02% in 2019, then fell 22.98% in 2023.
• Over 4 years, Operating Leases stood at $2.7 million in 2019, then surged by 44.54% to $3.9 million in 2020, then decreased by 29.45% to $2.7 million in 2022, then retreated by 22.98% to $2.1 million in 2023.
• According to Business Quant data, Operating Leases over the past three periods registered $2.1 million, $2.4 million, and $2.4 million for Q4 2023, Q3 2023, and Q2 2023 respectively.